Alternative, age- and viral load-related routes of nelfinavir resistance in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy

Pediatric Infectious Disease Journal

Volumn 23, Issue 11, 2004, Pages 1057-1059

  Machado, Elizabeth S ^a,b   Lambert, John S ^d   Afonso, Adriana O ^b   Cunha, Silvia M ^c   Oliveira, Ricardo H ^c   Tanuri, Amilcar ^b   Sill, Anne M ^d   Costa, Antonio J L ^a   Soares, Marcelo A ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Laboratório de Virologia Molecular   (Brazil)

^c Instituto de Puericultura e Pediatria Martagao Gesteira   (Brazil)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

Children; Human immunodeficiency virus type 1; Nelfinavir; Resistance mutations

Indexed keywords

NELFINAVIR; RITONAVIR; SAQUINAVIR;

AGE; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; UNINDEXED SEQUENCE; VIRUS LOAD; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECT; EPIDEMIOLOGY; GENETICS; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MUTATION; PRESCHOOL CHILD; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; NELFINAVIR; PHARMACOGENETICS; RISK FACTORS; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 16544366558     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000145874.88351.0f     Document Type: Article

References (10)

1. Patick AK, Duran M, Cao Y, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother. 1998;42:2637-2644.
2. Perrin V, Mammano F. Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants. J Virol. 2003; 77:10172-10175.
3. Saah AJ, Haas DW, DiNubile MJ, et al. Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy. J Infect Dis. 2003;187:1157-1162.
4. Clotet B, Ruiz L, Martinez-Picado J, Negredo E, Hill A, Popescu M. Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts. HIV Clin Trials. 2002;3:316-323.
5. Gomes P, Diogo I, Goncalves MF, et al. Different pathways to nelfinavir genotypic resistance in HIV-1 subtypes B and G. Presented at the 9th Conference on Retrovirus and Opportunistic Infections, 2002; Seattle. Abstract 46.
6. Eshleman SH, Krogstad P, Jackson JB, et al. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir [Pediatric AIDS Clinical Trials Group 377]. J Infect Dis. 2001;183:1732-1738.
7. Pillay D, Walker AS, Gibb DM, et al. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for treatment of AIDS [PENTA] 5 trial. J Infect Dis. 2002;186:617-625.
8. Bergshoeff AS, Fraaij PL, van Rossum AM, et al. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications. Antivir Ther. 2003;8:215-222.
9. Floren LC, Wiznia A, Hayashi S, et al. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics. 2003;112:e220-e227.
10. McIntosh K, Shevitz A, Zaknun D, et al. Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatric Infect Dis J. 1996;15:1087-1091.